BPCR — Biopharma Credit Income Statement

0.000.00%

Last trade - 00:00

FinancialsConservativeMid CapNeutral

Annual income statement for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	151	110	104	218	136
Cost of Revenue
Gross Profit	123	91.4	88	184	110
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	28.6	20.9	18.9	35.8	27.3
Operating Profit	122	89.1	85	182	108
Net Income Before Taxes	122	89.1	85	182	108
Provision for Income Taxes
Net Income After Taxes	122	89.1	85	182	108
Net Income Before Extraordinary Items
Net Income	122	89.1	85	182	108
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	122	89.1	85	182	108
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.088	0.065	0.062	0.134	0.083
Dividends per Share
Special Dividends per Share